Integer Holdings Corp (NYSE:ITGR) Q2 2025 Earnings: Revenue Beat, EPS In Line, Shares Drop 5% in Pre-Market

Integer Holdings Corp (NYSE:ITGR) Reports Q2 2025 Results: Revenue Beat, EPS In Line, Shares Decline

Integer Holdings Corp delivered a mixed performance in its second-quarter 2025 earnings report, with revenue surpassing analyst expectations but earnings per share (EPS) meeting consensus estimates. Despite the top-line beat, the stock faced downward pressure in pre-market trading, reflecting investor caution amid broader market sentiment.

Key Earnings Highlights

• Revenue: $476.5 million, up 11.4% year-over-year and slightly above the consensus estimate of $473.7 million.
• EPS (Non-GAAP): $1.55, matching analyst expectations of $1.58.
• Full-Year Guidance: The company raised its midpoint outlook for adjusted operating income and EPS, signaling confidence in continued profitability. Full-year revenue is projected at approximately $1.86 billion, aligning closely with analysts’ forecast of $1.906 billion.

Market Reaction

Following the earnings release, shares of Integer Holdings fell nearly 5% in pre-market trading, suggesting investor disappointment despite the revenue beat. The muted reaction to the EPS figure—while in line—may indicate concerns over margin pressures or future growth sustainability. Over the past month, the stock has declined 3.9%, reflecting broader sector volatility or pre-earnings skepticism.

Outlook vs. Analyst Estimates

The company’s upward revision of its full-year adjusted operating income and EPS guidance suggests management sees stronger profitability ahead. However, the revenue outlook remains steady at $1.86 billion, slightly below the analyst consensus of $1.906 billion. For Q3 2025, analysts expect revenue of $483.1 million and EPS of $1.70, which will be a key benchmark for the company’s next earnings report.

Press Release Summary

Integer Holdings emphasized continued sales and profit growth in Q2, driven by demand in its medical device and components business. The company highlighted strength across its Cardio & Vascular and neuromodulation segments, reinforcing its position in the medical technology sector.

For a deeper dive into Integer Holdings’ earnings estimates and historical performance, visit the earnings estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.